Advertisement
Canada markets close in 2 hours 22 minutes

  • S&P/TSX

    22,308.41
    -67.42 (-0.30%)
     

  • S&P 500

    5,215.78
    +1.70 (+0.03%)
     

  • DOW

    39,479.19
    +91.43 (+0.23%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.09%)
     

  • CRUDE OIL

    78.41
    -0.85 (-1.07%)
     

  • Bitcoin CAD

    82,627.62
    -2,182.97 (-2.57%)
     

  • CMC Crypto 200

    1,254.34
    -103.67 (-7.37%)
     

  • GOLD FUTURES

    2,375.30
    +35.00 (+1.50%)
     

  • RUSSELL 2000

    2,055.36
    -18.27 (-0.88%)
     

  • 10-Yr Bond

    4.5020
    +0.0530 (+1.19%)
     

  • NASDAQ

    16,317.72
    -28.54 (-0.17%)
     

  • VOLATILITY

    12.73
    +0.04 (+0.32%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6786
    +0.0008 (+0.12%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS DOW EYES GAIN FOR 8TH STRAIGHT SESSION

U.S. consumer sentiment tumbles in May as inflation, interest rate worries take hold

Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

Prosper Junior Bakiny, The Motley Fool
·4 min read
Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.

Continue reading